The World Health Organization (WHO) has recently approved the inclusion of the VIASURE Monkeypox Virus Real Time PCR Detection Kit in the list of in vitro diagnostic devices authorized for use in public health emergency situations (EUL).
Monkeypox is a disease that continues to be under health surveillance in several countries, especially in Central and Eastern Africa due to its prevalence.
Although 38,671 cases of monkeypox have been reported worldwide so far this year, it is not considered a global epidemic. Nevertheless, the WHO continues to closely monitor the virus. This surveillance work includes the development of these lists of diagnostic tests considered essential by this organization.
Inclusion in this list acknowledges the quality, safety, and performance of our VIASURE Monkeypox Virus Real Time PCR Detection Kit, enabling its acquisition by international organizations and laboratories that are part of the WHO’s global surveillance network.
This product has been developed and marketed by Certest since 2022 through Viasure, its specialized Molecular Biology unit. It offers fast, specific, and reliable diagnostics—capable of distinguishing monkeypox from other similar diseases, facilitating rapid patient diagnosis and epidemiological control.
Moreover, it’s worth noting that the kit includes lyophilized reagents, allowing it to be stored at room temperature. This is a significant advantage, especially considering that countries with the highest incidence of this virus often lack optimal storage conditions.
About Certest
Certest Biotec is a biotechnology company founded in 2002 in Zaragoza (Spain), focused on the development, manufacturing, and commercialization of IVD and biotech products, as well as on the diagnosis of infectious diseases.
Certest Biotec consists of four divisions, including Raw Materials, Immunodiagnostics (Rapid Tests, Turbidimetry, and CLIA), Molecular Biology and NGS under the VIASURE brand, and Pharma.
With an annual turnover of more than 38 million euros in 2024, it has more than 25,000 square meters of facilities and more than 300 employees, enabling it to be present in more than 130 countries through its network of distributors.
Certest Biotec stands out in its sector for its strong commitment to R&D, reinvesting almost 15% of its annual profits to improve the efficiency of its production processes and adapt to the constant changes in the market.
